Analysis
Two biotech IPOs priced inside the same week, and both moved the same direction: bigger and higher than planned. BlossomHill Therapeutics upsized its offering by roughly 50%, raising $150 million against an original $100 million target, according to BioSpace. Braveheart Bio priced at $18 a share, above its original $15-$17 range, raising $382.5 million against a roughly $300 million target -- both detailed in Pulse's coverage this week.
Two data points aren't a trend line on their own, but the direction matters after two years -- 2024 and 2025 -- in which biotech IPOs mostly priced at or below range, when they priced at all, and a wave of offerings got shelved rather than tested against a skeptical market. Both BlossomHill and Braveheart cleared their upsized targets in the same seven-day window, and both did it without a blockbuster efficacy readout already in hand -- neither company's lead asset has yet reported pivotal human trial data.
That's the real signal in the numbers: investors are underwriting biotech IPO demand again on story and management team, not just on data already in hand, which is exactly the kind of forward-looking risk appetite that dried up across 2024 and 2025. Whether it holds through the rest of August depends entirely on how the next handful of biotech offerings price -- and, eventually, on what the trial data these two companies haven't yet reported actually shows.